It seems that diabetes research and treatment inventions never slow down. Which could be considered a good thing, both by patients who may benefit from them, and by the pharmaceutical companies who pocket big bucks from them.

Yet another diabetes medication is on the horizon, an oral treatment designed to treat Type 2. Researchers believe the medicine is an innovation in diabetes treatment.

The mechanism of action of DPP-4 inhibitors is distinct from that of any currently available class of glucose lowering agents.

Sitagliptin is a potent and highly selective DPP-4 inhibitor. DPP-4 inhibitors work by enhancing a natural body process that lowers blood sugar, the incretin system. When blood sugar is elevated, incretins work in two ways to help the body regulate high blood sugar levels: they trigger the pancreas to increase insulin and signal the liver to stop producing glucose.

Would you be willing to try it?